Relapsing oral and genital ulcers (OGUs) represent the stigmata of Behçet’s disease (BD) and may be very painful, affecting both quality of life and relationships. A wide number of topical and immunosuppressive drugs can be used to treat ulcers, but failures are commonly reported. The efficacy of the phosphodiesterase-4 inhibitor apremilast has been proven in OGUs of BD in two randomised clinical trials (RCTs), whereas only two case reports are available until now. We aimed at evaluating the real-world effectiveness of apremilast in BD patients with OGUs refractory to conventional and/or biological treatments
Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease
Emmi G.;
2019-01-01
Abstract
Relapsing oral and genital ulcers (OGUs) represent the stigmata of Behçet’s disease (BD) and may be very painful, affecting both quality of life and relationships. A wide number of topical and immunosuppressive drugs can be used to treat ulcers, but failures are commonly reported. The efficacy of the phosphodiesterase-4 inhibitor apremilast has been proven in OGUs of BD in two randomised clinical trials (RCTs), whereas only two case reports are available until now. We aimed at evaluating the real-world effectiveness of apremilast in BD patients with OGUs refractory to conventional and/or biological treatmentsFile in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
